ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug Lupuzor
Chief executive Dimitri Dimitriou said Avion had a strong track record of taking late stage drugs through the regulatory process and onto commercialisation
Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 6 of 16
Immupharma steadfast in belief Lupuzor has commercial merit
Lupuzor did work well in certain patients, chiefly those who were antibody-positive
ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor
The drug developer also recently raised £2.66mln from its institutional investor, Lanstead Capital, to help execute its corporate strategy
Archive
Proactive news snapshot: Seeing Machines, Xpediator, Physiomics...
A glance at some of the day's highlights from the Proactive Investors newswire
VR group Immotion flags strategy shift as it focuses on long-term partnerships
In future, the focus will be on revenue sharing partnerships to roll-out its virtual reality pods into high footfall locations
Investments and investor services
FTSE 100 closes lower but BP top gainer after Q2 results beat expectations
The FTSE 100 index closed 39.84 points lower on the day at 7,646, while the midcap FTSE 250 index plunged almost 112 points to close at 19,774
Archive
Proactive news snapshot: Union Jack Oil, Oncimmune, Ariana Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Angus Energy considers sale of Brockham licences after disappointing drilling programme
A look at the day's major movers, including Rose Petroleum, Craneware, CVS, Adept4, Merlin, Mirriad and Costain
ImmuPharma jumps as follow-up study confirms safety of flagship lupus drug
After Lupuzor missed its primary endpoint in a phase III trial last year, ImmuPharma has been working hard to build a data package for the drug which it can take to regulators
Investments and investor services
FTSE 100 closes higher on day and week as world leaders meet
The mid-cap FTSE 250 added over 147 points to close at 19,462 on Friday
Archive
Serco's acquisitions and contract wins will be in focus on Thursday
Serco has already flagged that it expects its strong order intake to boost revenue in 2019 after several years of declines.
Archive
Proactive news snapshot: 88 Energy, Tekcapital, AFC Energy, SDX Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Kibo Energy the day's top riser as its moves to secure total ownership of the Bordersley project
A look at the day's major movers, including 88 Energy, Two Shields, Inland Homes, Avingtrans, Creightons, RM2 and RPS Group
ImmuPharma raises around £2.66mln from subscription agreement with institutional investor, Lanstead Capital
It said the proceeds of the subscription will be used primarily to fund the execution of its corporate strategy, including progressing Lupuzor through both corporate partnerships and regulatory pathways
Archive
FTSE 100 still stuck in neutral; G20 meeting can't come soon enough
Bitcoin is up more than 10% but the shine has come off gold a bit
Archive
News from FirstGroup, Stagecoach to drive corporate diary in coming week
Aside from the two mid-cap transport operators, blue chip contractor Bunzl will also issue a trading update, while the macro focus will be on the G20 meeting in Japan
Archive
Proactive news snapshot: Strategic Minerals, Westminster Group, Victoria Oil & Gas, ImmuPharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Royal Mail rises after stamp of approval from Liberum
A look at the day's major movers, including Headlam, Old Mutual, Caledonian Trust, Westminster Group, Luceco, Strategic Minerals, Tarsus and Mothercare
ImmuPharma continuing to talk with potential partners
The drug developer is assessing the best route forward for its lead drug, a treatment for the autoimmune disease, Lupus
Investments and investor services
Thomas Cook slumps again as debt-for-equity swap or emergency rights issue is expected
A look at the day's major movers, including Future, Capital & Regional, Tiger Resource, Metro Bank, eve Sleep, Maistro and Staffline